Press Releases

First detailed, empirical analysis of Class 1 epitopes presented by SARS-Cov-2 infected cells which define the T-Cell repertoire necessary for cytotoxic T-Cell function MHC expression library provides an accurate basis for COVID-19 T-Cell vaccine and related diagnostics development Doylestown PA, USA and Abingdon, Oxon, UK, 15 September 2020– Emergex Vaccines Holding Limited (‘Emergex’), a company […]

First identification of epitopes which shape CD8 T cell response to commercial live attenuated vaccine has implications across RNA virus vaccine development Vaccine primes immune system against T cell epitopes that would be minor or subdominant in a natural infection and are derived from internal proteins Abingdon, UK and Rio de Janeiro, Brazil, 19 August […]

Emergex publishes three White Papers highlighting the case for developing set-point vaccines to create a universal coronavirus vaccine

Emergex today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis.

Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire.

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine.

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.

Emergex Vaccines Holding Limited (“Emergex”), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business.

Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.